APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Citation for published version:
Petty, RD, Samuel, LM, Murray, GI, MacDonald, G, O'Kelly, T, Loudon, M, Binnie, N, Aly, E, McKinlay, A, Wang, W, Gilbert, F, Semple, S, Collie-Duguid, ESR & Semple, S 2009, 'APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling' BMC Cancer, vol 9, pp. 434. DOI: 10.1186/1471-2407-9-434

Digital Object Identifier (DOI):
10.1186/1471-2407-9-434

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
BMC Cancer

Publisher Rights Statement:
© 2009 Petty et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Russell D Petty*1,2, Leslie M Samuel1,2, Graeme I Murray1, Graham MacDonald1,2, Terrence O’Kelly3, Malcolm Loudon3, Norman Binnie3, Emad Aly3, Aileen McKinlay3, Weiguang Wang5, Fiona Gilbert1,4, Scot Semple1,4 and Elaina SR Collie-Duguid*1

Address: 1Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK, 2Departments of Oncology, Aberdeen Royal Infirmary, Aberdeen, UK, 3Surgery, Aberdeen Royal Infirmary, Aberdeen, UK, 4Clinical Radiology, Aberdeen Royal Infirmary, Aberdeen, UK and 5University of Wolverhampton, Wolverhampton, UK

Email: Russell D Petty* - r.d.petty@abdn.ac.uk; Leslie M Samuel - l.samuel@nhs.net; Graeme I Murray - g.i.murray@abdn.ac.uk; Terrence O’Kelly - tokelly@nhs.net; Malcolm Loudon - malcolm.loudon@arh.grampian.scot.nhs.uk; Norman Binnie - Norman.Binnie@NHS.net; Emad Aly - emad.aly@nhs.net; Aileen McKinlay - aileen.mckinlay@nhs.net; Weiguang Wang - w.wang2@wlv.ac.uk; Fiona Gilbert - f.j.gilbert@abdn.ac.uk; Scot Semple - scott.semple@ed.ac.uk; Elaina SR Collie-Duguid* - e.collie-duguid@abdn.ac.uk

* Corresponding authors

Published: 11 December 2009

BMC Cancer 2009, 9:434 doi:10.1186/1471-2407-9-434

Received: 14 April 2009
Accepted: 11 December 2009

This article is available from: http://www.biomedcentral.com/1471-2407/9/434

© 2009 Petty et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: 5-Fluorouracil (5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience of administration facilitate use, however clinical resistance is a major limitation. Investigation has failed to fully explain the molecular mechanisms of resistance and no clinically useful predictive biomarkers for 5FU resistance have been identified. We investigated the molecular mechanisms of clinical 5FU resistance in colorectal adenocarcinoma patients in a prospective biomarker discovery project utilising gene expression profiling. The aim was to identify novel 5FU resistance mechanisms and qualify these as candidate biomarkers and therapeutic targets.

Methods: Putative treatment specific gene expression changes were identified in a transcriptomics study of rectal adenocarcinomas, biopsied and profiled before and after pre-operative short-course radiotherapy or 5FU based chemo-radiotherapy, using microarrays. Tumour from untreated controls at diagnosis and resection identified treatment-independent gene expression changes. Candidate 5FU chemo-resistant genes were identified by comparison of gene expression data sets from these clinical specimens with gene expression signatures from our previous studies of colorectal cancer cell lines, where parental and daughter lines resistant to 5FU were compared. A colorectal adenocarcinoma tissue microarray (n = 234, resected tumours) was used as an independent set to qualify candidates thus identified.

Results: APRIL/TNFSF13 mRNA was significantly upregulated following 5FU based concurrent chemo-radiotherapy and in 5FU resistant colorectal adenocarcinoma cell lines but not in radiotherapy alone treated colorectal adenocarcinomas. Consistent with APRIL's known function as an autocrine or paracrine secreted molecule, stromal but not tumour cell protein expression by
immunohistochemistry was correlated with poor prognosis (p = 0.019) in the independent set. Stratified analysis revealed that protein expression of APRIL in the tumour stroma is associated with survival in adjuvant 5FU treated patients only (n = 103, p < 0.001), and is independently predictive of lack of clinical benefit from adjuvant 5FU [HR 6.25 (95%CI 1.48-26.32), p = 0.013].

Conclusions: A combined investigative model, analysing the transcriptional response in clinical tumour specimens and cancers cell lines, has identified APRIL, a novel chemo-resistance biomarker with independent predictive impact in 5FU-treated CRC patients, that may represent a target for novel therapeutics.

Background
Significant progress has been made recently in the systemic treatment of colorectal adenocarcinoma (CRC). There are currently 8 agents licensed for use in the US and Europe 5-fluorouracil (5FU), floxuridine, capicitabine, irinotecan, oxaliplatin, cetuximab, panitumumab and bevacizumab [1]. Combination therapy is the standard of care for both early and advanced disease [1]. 5FU, or an oral analogue capicitabine, is a component of the majority of combination regimens and the low toxicity, ease and convenience of administration, favour its clinical use. However, a modest response rate due to clinical resistance to 5FU is a major limitation. Older studies with 5FU monotherapy demonstrate that the majority of CRC patients treated will not benefit from 5FU, for example the objective response rate to 5FU or capicitabine monotherapy in advanced CRC is 20% [1].

Identification of the clinically important mechanisms of resistance to 5FU would allow better selection of patients for 5FU therapy and the rationale design of targeted therapies to overcome resistance, and thus increase the proportion of patients deriving benefit from 5FU. A predictive biomarker for clinical 5FU resistance would clearly be useful, but progress has been limited in this area and investigation has thus far failed to fully explain the molecular mechanisms that are important for clinical 5FU resistance [2-4]. Preclinical and clinical studies have mainly focussed upon molecules concerned with 5FU metabolism (Dihydropyrimidine dehydrogenase (DPD), Thymidine phosphorylase (TP)) or Thymidylate Synthase (TS), a well characterised 5FU target [3,4]. Clinical studies in colorectal cancer, assessing these molecules by a variety of techniques (IHC, RT-PCR, ELISA, genotyping), while demonstrating correlation between benefit (such as response and survival) from 5FU or capicitabine, have so far failed either to demonstrate genuine clinical utility as predictive biomarkers or produce useful targeted agents [3]. Overall, given the widespread clinical use of 5FU or its oral formulations, there is still a need for novel discovery approaches in this area.

The global perspective provided by gene expression profiling has provided novel insights into the molecular mechanisms of clinical response to therapy in human cancers [5], although few studies have specifically addressed clinical therapy response in colorectal adenocarcinomas [6-10] and only 1 has analysed serial biopsies before and after treatment [8]. This report describes our prospectively designed discovery study, Aberdeen Microarray in Rectal Cancer Study-1 (AMRECS1) using a combined approach, identifying candidate molecules from clinical specimens and comparing them with our 5FU chemo-resistance data from cell line model systems [11]. We aimed to identify novel mechanisms of resistance to 5-fluorouracil (5FU) that are clinically relevant in CRC patients. Tumour biopsies were collected before and after pre-operative therapy in rectal cancer patients following staging and stratification with magnetic resonance imaging (MRI), to identify gene expression changes that occur following either 'short course' radiotherapy (SCRT) or 5FU-based concurrent chemo-radiotherapy (CRT). Gene expression profiles from these matched clinical specimens were compared with profiles generated from colorectal adenocarcinoma cell lines, both sensitive parental and derived daughter cell lines with increasing resistance to 5FU. Data is presented for the validation of one potential novel clinical 5FU resistance candidate APRIL/TNFSF13 in an independent set of 234 patients with colorectal cancer.

Methods
Patients, Follow up and Treatment
The study was approved by the North of Scotland Research Ethics Committee. Patients provided informed consent in accordance with the regulations and instructions of the North of Scotland Research Ethics Committee for study participation, including use and publication of results. Full clinicopathological details are provided in table 1 and 2 and in Additional File 1. Patients were selected for either SCRT or CRT based upon MRI staging features [12]. All the radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Surgery was performed either the following week, for SCRT patients, or 6 to 8 weeks after completion of chemo-radiotherapy.
Gene expression profiling

Tumour biopsies were collected at the time of endoscopic diagnosis of rectal adenocarcinoma and placed immediately into RNAlater (800 μl) (Ambion, Austin, Texas). Tumour biopsies collected at time of curative surgical resection were placed immediately into normal saline and a pathologist provided a representative tumour biopsy, which was placed immediately into RNAlater within 30 minutes (800 μl). Tissues were stored in RNALater at 4°C overnight (16-18 hours), then washed in 500 μl ice cold RNase free PBS (Ambion, Austin, TX) and snap frozen in liquid nitrogen. Long-term storage of tissues was at -80°C. Before RNA extraction, histological diagnosis and features were confirmed by frozen section histology. Extraction and purification of total RNA was performed using TRI-ZOL reagent (Invitrogen, Carlsbad, CA) and RNeasy Microkits (Qiagen, Venlo, The Netherlands), according to the manufacturer’s instructions. Quantification of total RNA was performed using spectrophotometry (260/280 ratio 1.9 to 2.2 for all samples). Quality of total RNA and cRNA was assessed using a BioAnalyser 2100 (Agilent technologies, Palo Alto, CA). Target preparation for the Affymetrix Genechips™ was according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). Specifically, 4 μg of total RNA was used for reverse transcription and synthesis and amplification of biotin labelled cRNA using the One cycle target labelling and control reagents. Clean-up of biotin-cRNA was performed with RNeasy Minikits (Qiagen, Venlo, The Netherlands). Fragmentation was performed using 20 μg of biotin-labelled cRNA. A hybridisation cocktail was prepared from 15 μg which was first hybridised to Test 3 GeneChips™ to assess sample quality (GAPDH 3':5' < 3 and Actin 3': 5' < 3) and then to HGU133 Plus2.0 GeneChips™ (10 μg) for gene expression analysis. Procedures for hybridisation, washing, staining and scanning of chips were carried out according to standard protocols (Affymetrix, Santa Clara, CA).

Analysis of gene expression profiling data

Analysis of the gene expression data is described in Additional file 2 and as described previously [11,13]. Raw data for gene expression is provided in MIAME complaint format in Array express, accession number E-MEXP-1901.
Immunohistochemistry
Description of the Tissue Microarray (TMA) is provided in previous publications [14]. A total of 268 colorectal tumours and 50 normal colon cores are represented, with 1 core per case. During the staining procedure 34 (13%) tumour cores were lost, leaving cores from 234 patients available for assessment. Antigen retrieval was performed by microwaving in 10 mM citrate (pH 6.0) for 20 minutes. An autostainer (Dakocytomation, Glostrup, Denmark) was used for staining the sections using a mouse monoclonal primary antibody for human APRIL/TNFSF13 (1:60 dilution, Abcam, Cambridge, UK) and Chemate-Envision detection system (Dakocytomation, Glostrup, Denmark), according to the manufacturer's instructions. All sections were double scored by 2 independent investigators who were blinded to the clinical data. Scoring discrepancies were resolved by examination of sections at a double-headed microscope. Sections were scored positive or negative for tumour and/or stromal staining. In addition tumour staining intensity was scored as weak, moderate or strong.

Statistical analysis
Continuity corrected $\chi^2$ test, with Fisher’s exact test where appropriate, was used for binary categorical variables, Pearson’s $\chi^2$ test for non-binary categorical variables and Student’s t-test for numerical variables. Kaplan-Meier curves were constructed to assess survival and the log rank test to assess statistical significance. The Cox proportional hazards model was used for multivariate analysis of survival. Two-sided $p$ values of less than 0.05 were considered significant. All analyses were performed using SPSS for Windows, version 13.0 (SPSS Inc, Chicago, IL).

Results
Chemo-radiotherapy or radiotherapy altered gene expression in rectal cancer
In a pilot transcriptomics study of rectal cancer patients, we used oligonucleotide microarrays to profile the expression of over 47000 transcripts representing 38562 human genes in rectal tumour biopsies before and after pre-operative treatment with CRT ($n = 4$ patients; table 1). Rectal tumour biopsies before and after SCRT ($n = 4$ patients; table 1) were also analysed to enable comparison of gene expression changes in patients treated with 5FU-based chemo-radiotherapy with those observed in patients receiving radiotherapy alone. Rectal tumour biopsies, at diagnosis and surgical resection, from two patients who did not undergo any pre-operative treatment (table 1) were used to identify treatment-independent gene expression changes.

SOPs were developed and validated to allow collection of tissues at endoscopic diagnosis and at surgical resection, whilst preserving RNA integrity. Total RNA extracted from these tissues (10-30 mg) in this pilot study provided sufficient yield (8 to 40 ug) and quality total RNA for gene expression analysis on Affymetrix oligonucleotide microarrays. Raw gene expression data is provided in MIAME complaint format in Array express, accession number E-MEXP-1901.

Threshold and probabilistic filtering of the data (see Additional file 2) identified 86 genes (91 probe sets) consistently, significantly and specifically altered following 5FU-based CRT and 51 genes (58 probe sets) following SCRT (see Additional File 3 for details of genes and fold change following therapy). Hierarchical cluster analysis, highlights 2 distinct clusters of genes up-regulated or down-regulated following CRT (figure 1A) or SCRT (figure 1B). The expression profiles of each of these gene sets clearly separates pre- and post-treatment samples into two primary clusters for each treatment group (figure 1). A matrix analysis (DMTv1.0, Affymetrix, CA) of therapy-altered gene sets identified using threshold filtering alone (see Additional file 2; 697 probe sets in CRT group and 570 in SCRT group, including 86 overlapping), reveals that these genes sets are significantly non-overlapping ($p = 0.010$), demonstrating highly distinct alterations to the tumour transcriptome following treatment with SCRT or 5FU-based CRT.

The biological functions of the CRT and SCRT altered gene sets were evaluated (additional file 4). While many of the same key biological pathways are identified in each treatment group, consistent with a co-ordinated transcript-

Table 2: Resected colorectal adenocarcinoma patients analysed by immunohistochemistry for APRIL protein expression on tissue microarray

| Variable | Frequency/median(range) |
|----------|-------------------------|
| **Age**  | 71 years (22-92)        |
| **Gender** |                         |
| Male     | 121                     |
| Female   | 113                     |
| **Histological Grade** |                 |
| Poor     | 27                      |
| Moderate | 199                     |
| Well     | 8                       |
| **Tumour site** |                 |
| Proximal colon | 79                      |
| Distal colon  | 86                      |
| Rectum   | 69                      |
| **Stage** |                        |
| I        | 46                      |
| II       | 86                      |
| III (adjvant chemotherapy)$^1$ | 102 (63) |
| N2       | 48                      |

$^1$In this series 63/102 (62%) Stage III patients received adjuvant chemotherapy with 5FU
tional response, there are some pathways only altered following CRT and some pathways (cell death and cell cycle) where there is numerically significantly more change in gene expression in the CRT treated patients (additional file 4).

This represents an initial pilot study of the first samples in our rectal cancer patient cohort. It is important to note that the small sample size, necessitates validation of these candidate gene expression changes in a larger cohort. The primary aim of this study was to identify candidate 5FU resistance markers in rectal tumours, in a pilot discovery study using a transcriptome-wide approach and to validate key candidate/s that may have mechanistic relevance in a larger cohort. Identification and validation of one such marker is described below.

**APRIL/TNFSF13 in colorectal cancer**

As we were interested in potential mediators of 5FU resistance in rectal tumours *in vivo*, we further mined the gene expression analysis using a pathway focussed analysis of cell deaths pathways, including those involved in regulation or execution of caspase-dependent apoptotic, caspase-independent and necrotic cell death genes (n = 2177 genes; additional file 5). Threshold and probabilistic filtering of the gene expression data identified 17 cell death genes consistently and significantly altered in rectal tumours following chemo-radiotherapy (additional file 6). Several of these genes have been implicated in colorec-
APRIL has been characterised as promoting cell survival and cell proliferation and this involves NFκB activation [15-19]. In addition, APRIL mRNA has been shown to be increased in colorectal tumours compared to normal mucosa [17]. These data supported further investigation of a putative functional role for APRIL in clinical 5FU chemo-resistance.

APRIL protein expression was evaluated in 234 resected colorectal adenocarcinomas and 50 normal colon or rectal mucosa specimens (table 2). APRIL protein was not expressed in normal colon tissues but was, as expected, expressed in both colorectal tumour cells and the tumour stroma (Table 3 and figure 2). Tumour cell staining was observed in the cytosol and membrane of tumour cells (figure 2). Stromal staining was evident in both the extracellular matrix and also in stromal cells (figure 2).

**APRIL, a putative 5FU chemo-resistance factor and predictive biomarker in 5FU treated colorectal cancer patients**

We examined the relationship between APRIL protein expression and survival after surgical resection. We prospectively determined that we would evaluate both tumour cell and tumour stromal expression of APRIL protein due to its characterized biological function as a secreted autocrine and/or paracrine molecule. There was no significant association between tumour cell or stromal expression (p = 0.048). In tumour cells expressing APRIL, intensity correlation between tumour cell and stromal expression (p = 0.048). There was no significant association between tumour cell or stromal staining and age, gender, histological grade, tumour site or Duke's stage (all p > 0.20. Data not shown).

In light of our hypothesised role of APRIL in 5FU resistance, we stratified the Stage III patients according to whether or not they received adjuvant chemotheraphy with 5FU following surgical resection of their primary tumour. Stage I and II patients did not receive adjuvant chemotherapy in this series. Tumour stroma expression of APRIL protein is only associated with worse survival in those patients treated with 5FU and there is no relationship with survival in Stage III patients not treated with adjuvant chemotherapy (n = 102, p < 0.001, figure 3c). In 5FU treated Stage III patients (n = 63), median survival for stroma positive is 36 months with predicted 5 year survival 42.0% (95% confidence interval 11.8% - 72.2%); median survival not yet reached for stroma negative and predicted 5 year survival is 85% (95% confidence intervals 71.7%-98.6%). Multivariate analysis confirms expression of APRIL protein in the tumour stroma as an independent prognostic factor in chemotherapy treated Stage III patients, with a HR of 6.25 (95% CI 1.48-26.32, p = 0.013, table 4).

The survival of the 5FU treated Stage III colorectal cancer patients who express APRIL protein in the tumour stroma parallels survival observed in Stage III patients who did not receive adjuvant therapy (treatment decision due to patient or physician preference), irrespective of APRIL protein expression (figure 3c). In contrast, the APRIL negative patients have an excellent predicted 5 year survival and have a clear and statistically significant (p < 0.001) survival benefit compared to untreated or APRIL positive 5FU treated patients (figure 3c). These data suggest that APRIL has no prognostic impact in colorectal cancer treated by surgical resection alone, but has predictive impact for benefit from adjuvant 5FU in colorectal cancer patients.

**Discussion**

Global gene expression profiling of clinical response to therapy has provided a useful means for biomarker and novel target discovery in several solid tumours [5,13]. The
work described in this paper has used and extended this experimental approach to rectal adenocarcinomas. The data presented constitutes an analysis from gene expression profiling of prospectively collected pre- and post-treatment tumour specimens from patients with rectal adenocarcinomas receiving pre-operative therapy.

Since a small number of rectal adenocarcinomas have been profiled (n = 10), stringent and focussed analysis of the microarray data was applied to identify leads for further investigation. This included hypothesis-driven focus on cell death pathways and comparison with our previously published cell line work. The key candidate was subsequently validated in a larger independent set (n = 234) using a different technique (immunohistochemistry).

The biological validity of the experimental model and the data is confirmed by the finding of significant alterations in the gene expression of previously implicated molecules and pathways, for example p21 which has been implicated in numerous studies [20-25]. The biological pathways identified (information 3 and 4) suggest a coordinated transcriptional response to radiotherapy- and CRT- induced cellular stress, consistent with other reports involving gene expression profiling in cell lines and several different cancer types [2,11,13,25-29]. We hypothesize that this reflects distinct biological effects of these two treatments. However, the possibility of effects due to time course differences in the tumour sampling in each group cannot be excluded.

A supervised analysis of cell death genes, reveals shared genes and pathways. The analysis supports the hypothesis that initiation of cell death is a common final pathway resulting from a multitude of upstream responses to the insult and resultant cellular stress of cytotoxic chemotherapy or radiotherapy thereby accounting for gene expression overlap seen.

The majority of the genes identified in our analysis represent genes and pathways that have not previously been implicated in clinical response of rectal adenocarcinoma or as mechanisms of action or resistance to radiotherapy or 5FU or 5FU-based CRT. This is consistent with the findings of other gene expression profiling studies in rectal adenocarcinoma or other tumour types for radiotherapy or 5FU [6,8-11,26,28-30]. However, it is important to note that this discovery phase utilised a small sample cohort and the candidate gene expression changes require further validation in a larger independent cohort.

APRIL/TNFSF13 was found to be upregulated following CRT but not radiotherapy alone in rectal cancers and was also up-regulated in 5FU resistant cell lines in our previ-
ous studies [11]. The biological function of APRIL as a secreted molecule that has autocrine and paracrine functions to promote cell survival and proliferation and its previously documented expression in colorectal adenocarcinoma but not normal cells outside the immune system, supported it’s further investigation as a novel mechanism of 5FU action and resistance, and as a predictive biomarker [15-19,31-35].

This study found that expression of APRIL protein in colorectal tumour stroma was associated with worse survival, but only in those patient’s treated with adjuvant 5FU chemotherapy. This relationship was also maintained in a multivariate analysis of 5FU chemotherapy treated Stage III colorectal adenocarcinoma patients (HR 6.25, 1.47-26.31, p = 0.013), in which the Hazard ratio compares favourably to other previously published putative 5FU predictive biomarkers in colorectal cancer [2-4]. Tumour cell expression of APRIL was correlated with stromal staining but was not significantly associated with survival. Overall, APRIL appears to have no therapy independent prognostic impact in colorectal adenocarcinoma in this analysis.

Figure 3
APRIL protein expression in tumour stroma and survival of colorectal cancer patients. (a). Kaplan-Meier survival plots for tumour stroma APRIL protein expression analysed by immunohistochemistry of 234 colorectal cancer patients following surgical resection. (b) Stromal staining for APRIL in Stage III patients following surgical resection (n = 102) (c) Combined analysis of stage III patients (n = 102) stratified according to adjuvant therapy and tumour stroma APRIL protein. P value is log rank test.

| p<0.001 |
| -- |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
Within the limitations of a retrospective study, these results suggest that APRIL may have clinical utility as a predictive biomarker to select patients who would not benefit from adjuvant 5FU monotherapy. For example, currently adjuvant 5FU is used clinically in an empirical way without predictive biomarkers in stage III patients and in this paradigm the majority of patients with Stage III cancers will not benefit from 5FU. Therefore, the ability to identify some of these stage III patients who will not benefit from 5FU has clear potential clinical utility in optimising and individualising clinical use of 5FU in this setting. An important question is whether APRIL confers cross resistance to other active agents used to treat colorectal cancer, especially Oxaliplatin and Irinotecan, this would be potentially useful to guide 5FU combination adjuvant therapy in stage III patients, but especially in stage II patients where 5FU alone appears to have limited benefit.

The data allows us to hypothesise that APRIL may provide a useful novel therapeutic target. Morphological examination has suggested that positively staining stromal cells include lymphocytes and fibroblasts, but not endothelial cells. This is consistent with evidence indicating that APRIL is predominantly secreted and exerts its effects via cell surface receptors, acting in a paracrine or autocrine fashion [15-19,31-35].

Our data indicate that APRIL might be secreted by tumour cells or stromal cells within the tumour. The APRIL signalling mechanisms that may mediate tumour cell survival are not well characterised [32]. However, in vitro work in glioma cell lines and ex vivo studies in BCLL, has shown that APRIL stimulates proliferation and inhibits apoptosis in response to a wide range of stimuli, including CD95L, TRAIL and cytotoxic drugs and survival in B-CLL cells involves NFκB activation [15-19,31-34]. More recently it has been suggested that tumour infiltrating neutrophils may be an important source of APRIL production in solid tumours [35].

If APRIL is functional as an extracellular secreted molecule this makes it amenable to targeting with either a small molecule inhibitor or monoclonal antibody, as has been employed successfully for other targets in solid tumours e.g. bevacizumab against VEGF. An anti-APRIL targeted therapy may be useful in reversal of acquired 5FU resistance or in combination in patients whose tumours over-express the molecule.

The lack of therapy independent prognostic impact suggests that an anti-APRIL therapy may not have anticancer activity on its own, but the cell survival promoting activity may be more generally applicable to other therapeutic cell death stresses. Therefore, combination of an anti-APRIL agent with agents other than 5FU may be active, and our cell line data also suggest that they may be active in other tumour types, such as breast cancer.

**Conclusions**

In this study we have used a combined investigative model, analysing the transcriptional response in clinical tumour specimens from rectal adenocarcinomas and cancer cell lines, to identify APRIL, as a novel 5FU chemoresistance biomarker. We have validated its importance in an independent set of colorectal adenocarcinomas. This data supports further investigation of the clinical utility of APRIL as a predictive biomarker for 5FU resistance in colorectal adenocarcinomas and other solid tumour types and also as a target for novel therapeutics aimed at reversal of clinical resistance to 5FU and its oral analogues.

**Competing interests**

The authors declare that they have no competing interests.

---

**Table 4: Multivariate analysis using Cox proportional hazards regression model for adjuvant chemotherapy treated Stage III patients.**

| Variable                     | HR   | 95% Confidence Interval | p value |
|------------------------------|------|-------------------------|---------|
| Age (>70 vs <70)             | 1.006| 0.955-1.059             | 0.835   |
| Gender (Female vs Male)      | 0.532| 0.159-1.783             | 0.307   |
| Grade (poor vs moderate vs well) | N/A | N/A                     | 0.873   |
| Site (Proximal vs Distal)    | 5.015| 0.695-36.191            | 0.110   |
| APRIL Tumour Stroma Staining (positive vs negative) | 6.250 | 1.471-26.316 | 0.013 |
| APRIL Tumour Cell Staining (positive vs negative) | 0.64  | 0.200-2.044             | 0.452   |
Additional material

Additional file 1
Further details of Patients and Treatments. Clinicopathological, selection criteria, staging and chemotherapy and radiotherapy protocol details for patients in the study.
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S1.DOC

Additional file 2
Details of analysis of Gene Expression Profiling Data. Details of quality control, normalisation and analysis for identification of genes whose expression is consistently and significantly altered as a consequence of chemoradiotherapy or radiotherapy. Figure S2. Schematic to illustrate bioinformatic analysis performed to identify genes whose expression was consistently and significantly altered as a result of either neoadjuvant chemoradiotherapy or short course radiotherapy.
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S2.DOC

Additional file 3
Details of genes identified in analysis of rectal adenocarcinomas. Details of genes identified in analysis of rectal adenocarcinomas whose expression is consistently and significantly changed after treatment with chemoradiotherapy or radiotherapy. Table S3.1. List of 86 genes (91 probe sets) whose expression is consistently and significantly changed after treatment with chemoradiotherapy. Table S3.2 - List of 52 genes (58 probe sets) whose expression is consistently and significantly changed after treatment with short course radiotherapy.
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S3.DOC

Additional file 4
Biological pathways altered following neoadjuvant radiotherapy or chemoradiotherapy in rectal tumours. The number of genes in each biological pathway whose expression was altered following chemoradiotherapy or radiotherapy is shown. Gene ontologies (biological function) were assigned according to GO. Genespring v6.1, NetAffx, EntrezGene, RefSeq and literature searches using Medline and ISI. Table S4 - The number of genes in each biological pathway whose expression was altered following chemoradiotherapy or radiotherapy.
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S4.DOC

Additional file 5
Cell death gene list used for supervised gene expression analysis. Xcel file with list of identified 2177 genes involved in the control, regulation and execution of cell death (apoptotic and non-apoptotic forms) that were represented on the HGU1.3 Plus 2.0 GeneChip, using databases (GO, Genespring v6.1, RefSeq, EntrezGene) and literature searches (Medline and ISI).
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S5.XLS

Additional file 6
Details of Supervised analysis of Cell Death Pathways. Schematic representations to explain supervised bioinformatic analysis of cell death pathways. Figure S6. Schematic illustrating the bioinformatics analysis performed for the supervised analysis of cell death genes. GCOS v1.2 and Genespring v6.1.1 were used for the analyses. Table S6. List of Cell death genes identified in this analysis in CRT and SCRT treated rectal adenocarcinoma patients. Table S6.1. Genes identified as candidate novel mechanisms of 5FU chemoresistance or sensitivity from gene expression profiling experiments of 5FU resistant colorectal and breast cancer cell lines.
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S6.DOC

Additional file 7
Additional survival analyses for APRIL protein expression in colorectal adenocarcinomas. Kaplan-Meier survival plots for APRIL protein expression in tumour cells of colorectal adenocarcinom patients in stage I, II and APRIL stroma expression in Stage I and II Figure S7.1 Kaplan-Meier survival plots for APRIL immunohistochemistry showing no significant relationship for tumour cell protein expression and survival. All patients (n = 234), analysed according to intensity of APRIL staining in tumour cells [weak, moderate or strong (b)] or positive versus negative tumour cell staining (a), or stratified according to stage Dukes A/Stage I, Dukes B/Stage II and Dukes C/Stage III (c). Figure S7.2. Kaplan-Meier survival plots for APRIL immuno-histochemistry showing that positive staining in the tumour stroma shows no association with survival in Dukes’s A/Stage I (n = 46) or B/Stage II tumours (n = 86).
Click here for file
http://www.biomedcentral.com/content/supplementary/1471-2407-9-434-S7.DOC

Acknowledgements
This work was supported by The Friends of the Aberdeen and the North Centre for Oncology, Haematology and Radiotherapy (ANCHOR), Asso-
family, modulates death ligand-induced apoptosis. Cell Death Differ 2001, 8(4):403-410.
20. Fu CG, Tomingao Q, Nagowa H, Nita ME, Masaki T, Ishimaru G, et al.: Role of p53 and p21/WAF1/CIP1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998, 41(1):68-74.
21. Qiu H, Sirivong P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J: Molecular prognostic factors in rectal cancer treated with radiotherapy and surgery. Dis Colon Rectum 2000, 43(4):451-459.
22. Rau B, Saurm I, Lage H, Berger S, Schneider U, Hauptmann S, et al.: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiotherapy. J Clin Oncol 2003, 21(18):3391-3401.
23. Sogawa N, Takiguchi N, Koda K, Oda K, Satomi D, Kato K, et al.: Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol 2002, 20(6):1787-793.
24. Yoshikawa R, Yanagi H, Kusunoki M, Fujishita Y, Noda M, Hashimoto-Tamaoki T, et al.: Prognostic values of radiation-induced p53 in adjacent normal mucosa and p21WAF1/CIP1 expression in rectal cancer patients. Int J Oncol 2002, 21(6):1223-1228.
25. Wang W, McLeod HL, Cassidy J, Collie-Duguid E: Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 2007, 59(6):839-845.
26. Maxwell PJ, Longley DB, Lalti T, Boyer J, Allen W, Lynch M, et al.: Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003, 63(15):4602-4606.
27. Jansen MP, Koenigs JA, van Staveren IL, Dirkzwager-Kiel MM, Rittsler K, Look MP, et al.: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23(4):732-740.
28. Rieger KE, Huang G: Portrait of transcriptional responses to ultraviolet and ionizing radiation in human cells. Nucleic Acids Res 2004, 32(16):4786-4803.
29. Rieger KE, Hong WJ, Tusher VG, Tang J, Tibshirani R, Chu G: Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proc Natl Acad Sci USA 2004, 101(17):6635-6640.
30. Ding LH, Shingyooji M, Chen F, Chatterjee A, Kasai KE, Chen DJ: Gene expression changes in normal human skin fibroblasts induced by HZE-particle radiation. Radiat Res 2005, 164(4 Pt 2):523-526.
31. Kelsen DP, Ginsberg R, Rajek TF, Sheahan DG, Gunderson L, Mortimer J, et al.: Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer. N Engl J Med 1998, 339(27):1799-1804.
32. Mackay F, Ambrose C: The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003, 14(3-4):311-324.
33. Hahne M, Kazoaka T, Schroeter M, Hofmann K, Irmler M, Bodmer JL, et al.: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998, 188(6):1185-1190.
34. Stein IV, Lopez-Fraga M, Gusttando FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, et al.: APRIL modulates B and T cell immunity. J Clin Invest 2002, 109(12):1857-1859.
35. Mhawech-Fauceglia P, Allal A, Oudusi K, Andrews C, Herrmann FR, Huard B: Role of the tumor necrosis factor ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. Eur J Cancer 2008, 44(15):2097-2100.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/9/434/prepub